Dan Schulman addresses key considerations in orphan drug commercialization

Share on facebook
Share on twitter
Share on linkedin

Orphan drugs are different than mass-market therapies -- and so is their commercial strategy. Orphan drug manufacturers should engage patients throughout research, development and commercialization -- and hire specialized sales forces market the therapy to the most relevant physicians. Associate Partner Dan Schulman describes in Med Ad News the steps orphan drug manufacturers can take to ensure their life-saving treatments reach patients as quickly as possible.